Allergan Receives FDA Approval And Launches First Generic Version Of CRESTOR®

Allergan plc, a leading global pharmaceutical company, today confirmed that it has received final approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for rosuvastatin calcium 5, 10, 20 and 40 mg tablets, the generic version of AstraZeneca's CRESTOR® (rosuvastatin) tablets.  Following receipt of the FDA approval, Allergan is the first company to launch a generic version of CRESTOR® to customers in the U.S.

Link:
www.prnewswire.com/news-releases/allergan-receives-fda-approval-and-launches-first-generic-version-of-crestor-rosuvastatin-300260658.html